Trial Outcomes & Findings for Benefits of Microcor in Ambulatory Decompensated Heart Failure (NCT NCT04096040)

NCT ID: NCT04096040

Last Updated: 2025-01-08

Results Overview

Each time a subject's thoracic fluid index (TFI) exceeded a threshold for 3 consecutive days, a data update report was generated by the uCor management system. The site then confirmed its receipt of the data update by completing a case report form. At least 1 of these case report forms was completed for 56 subjects.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

265 participants

Primary outcome timeframe

90 days

Results posted on

2025-01-08

Participant Flow

Participant milestones

Participant milestones
Measure
uCor Wearers
Subjects wearing the uCor device
Overall Study
STARTED
265
Overall Study
COMPLETED
249
Overall Study
NOT COMPLETED
16

Reasons for withdrawal

Reasons for withdrawal
Measure
uCor Wearers
Subjects wearing the uCor device
Overall Study
Protocol Violation
12
Overall Study
Non-compliant site
4

Baseline Characteristics

Benefits of Microcor in Ambulatory Decompensated Heart Failure

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
uCor Wearers
n=249 Participants
Subjects wearing the uCor device
Age, Continuous
68.6 years
STANDARD_DEVIATION 13.1 • n=99 Participants
Sex: Female, Male
Female
105 Participants
n=99 Participants
Sex: Female, Male
Male
144 Participants
n=99 Participants
Race/Ethnicity, Customized
American Indian or Alaskan Native
1 participants
n=99 Participants
Race/Ethnicity, Customized
Asian
3 participants
n=99 Participants
Race/Ethnicity, Customized
Caucasian
135 participants
n=99 Participants
Race/Ethnicity, Customized
Black or African American
63 participants
n=99 Participants
Race/Ethnicity, Customized
Other
5 participants
n=99 Participants
Race/Ethnicity, Customized
Don't Know/ No Response
0 participants
n=99 Participants
Race/Ethnicity, Customized
Hispanic/ Latino
43 participants
n=99 Participants
Weight
205.2 pounds
STANDARD_DEVIATION 63.4 • n=99 Participants
Height
66.6 inches
STANDARD_DEVIATION 4.1 • n=99 Participants
Blood Pressure (Systolic)
126.2 mmHg
STANDARD_DEVIATION 20 • n=99 Participants
Blood Pressure (Diastolic)
72.2 mmHg
STANDARD_DEVIATION 12.1 • n=99 Participants
Heart Rate (per min)
77.1 beats per minute
STANDARD_DEVIATION 13.2 • n=99 Participants
Respiratory Rate (per min)
18 breaths per minute
STANDARD_DEVIATION 5.7 • n=99 Participants
Time Since Heart Failure Diagnosis
4.7 years
STANDARD_DEVIATION 5.8 • n=99 Participants
Ejection Fraction (Min)
41.3 percent of ejection fraction
STANDARD_DEVIATION 15.6 • n=99 Participants
Ejection Fraction (Max)
44.9 percent of ejection fraction
STANDARD_DEVIATION 15.7 • n=99 Participants
New York Heart Association(NYHA) Class
Class I
7 Participants
n=99 Participants
New York Heart Association(NYHA) Class
Class II
102 Participants
n=99 Participants
New York Heart Association(NYHA) Class
Class III
84 Participants
n=99 Participants
New York Heart Association(NYHA) Class
Class IV
2 Participants
n=99 Participants
New York Heart Association(NYHA) Class
Not Documented
54 Participants
n=99 Participants
Heart Failure Etiology
Ischemic
102 Participants
n=99 Participants
Heart Failure Etiology
Non-ischemic
130 Participants
n=99 Participants
Heart Failure Etiology
Mixed
13 Participants
n=99 Participants
Heart Failure Etiology
N/A or Unknown
4 Participants
n=99 Participants
Educational Level
Less than High School
57 Participants
n=99 Participants
Educational Level
High School
132 Participants
n=99 Participants
Educational Level
Bachelors or Associates
37 Participants
n=99 Participants
Educational Level
Graduate or Professional
13 Participants
n=99 Participants
Educational Level
N/A or Unknown
10 Participants
n=99 Participants
Employment Status
Employed
32 Participants
n=99 Participants
Employment Status
Student
0 Participants
n=99 Participants
Employment Status
Homemaker
2 Participants
n=99 Participants
Employment Status
Unemployed
63 Participants
n=99 Participants
Employment Status
Retired
152 Participants
n=99 Participants
Cardiac Device History
History of Implantable Cardioverter Defibrillator(ICD) · Yes
49 Participants
n=99 Participants
Cardiac Device History
History of Implantable Cardioverter Defibrillator(ICD) · No
200 Participants
n=99 Participants
Cardiac Device History
History of Implantable Cardioverter Defibrillator(ICD) · N/A or Unknown
0 Participants
n=99 Participants
Cardiac Device History
ICD Active at Enrollment · Yes
49 Participants
n=99 Participants
Cardiac Device History
ICD Active at Enrollment · No
0 Participants
n=99 Participants
Cardiac Device History
ICD Active at Enrollment · N/A or Unknown
200 Participants
n=99 Participants
Cardiac Device History
History of Pacemaker · Yes
45 Participants
n=99 Participants
Cardiac Device History
History of Pacemaker · No
204 Participants
n=99 Participants
Cardiac Device History
History of Pacemaker · N/A or Unknown
0 Participants
n=99 Participants
Cardiac Device History
Pacemaker Active at Enrollment · Yes
43 Participants
n=99 Participants
Cardiac Device History
Pacemaker Active at Enrollment · No
2 Participants
n=99 Participants
Cardiac Device History
Pacemaker Active at Enrollment · N/A or Unknown
204 Participants
n=99 Participants
History of Remote Heart Failure(HF) Monitor
Yes
2 participants
n=99 Participants
History of Remote Heart Failure(HF) Monitor
No
247 participants
n=99 Participants
History of Hypertension
Yes
233 Participants
n=99 Participants
History of Hypertension
No
14 Participants
n=99 Participants
History of Hypertension
Uknown
2 Participants
n=99 Participants
History of Diabetes
Yes
141 Participants
n=99 Participants
History of Diabetes
No
107 Participants
n=99 Participants
History of Diabetes
Unknown
1 Participants
n=99 Participants
History of Chronic Obstructive Pulmonary Disease (COPD)
Yes
86 Participants
n=99 Participants
History of Chronic Obstructive Pulmonary Disease (COPD)
No
157 Participants
n=99 Participants
History of Chronic Obstructive Pulmonary Disease (COPD)
Unknown
6 Participants
n=99 Participants
History of Transient Ischemic Attack (TIA)
Yes
33 Participants
n=99 Participants
History of Transient Ischemic Attack (TIA)
No
215 Participants
n=99 Participants
History of Transient Ischemic Attack (TIA)
Unknown
1 Participants
n=99 Participants
History of Chronic Kidney Disease (CKD)
Yes
118 Participants
n=99 Participants
History of Chronic Kidney Disease (CKD)
No
128 Participants
n=99 Participants
History of Chronic Kidney Disease (CKD)
Unknown
3 Participants
n=99 Participants
History of Angina
Yes
78 Participants
n=99 Participants
History of Angina
No
159 Participants
n=99 Participants
History of Angina
Unknown
12 Participants
n=99 Participants
History of Syncope
Yes
33 Participants
n=99 Participants
History of Syncope
No
208 Participants
n=99 Participants
History of Syncope
Unknown
8 Participants
n=99 Participants
History of Sudden Cardiac Arrest (SCA)
Yes
9 Participants
n=99 Participants
History of Sudden Cardiac Arrest (SCA)
No
237 Participants
n=99 Participants
History of Sudden Cardiac Arrest (SCA)
Unknown
3 Participants
n=99 Participants
History of Arrhythmia
Yes
153 Participants
n=99 Participants
History of Arrhythmia
No
88 Participants
n=99 Participants
History of Arrhythmia
Unknown
8 Participants
n=99 Participants
History of Myocardial Infarction (MI)
Yes
83 Participants
n=99 Participants
History of Myocardial Infarction (MI)
No
157 Participants
n=99 Participants
History of Myocardial Infarction (MI)
Unknown
9 Participants
n=99 Participants
History of Coronary Artery Bypass Graft (CABG)
Yes
48 Participants
n=99 Participants
History of Coronary Artery Bypass Graft (CABG)
No
199 Participants
n=99 Participants
History of Coronary Artery Bypass Graft (CABG)
Unknown
2 Participants
n=99 Participants
History of Percutaneous Coronary Intervention (PCI)
Yes
85 Participants
n=99 Participants
History of Percutaneous Coronary Intervention (PCI)
No
161 Participants
n=99 Participants
History of Percutaneous Coronary Intervention (PCI)
Unknown
3 Participants
n=99 Participants

PRIMARY outcome

Timeframe: 90 days

Population: data updates per subject

Each time a subject's thoracic fluid index (TFI) exceeded a threshold for 3 consecutive days, a data update report was generated by the uCor management system. The site then confirmed its receipt of the data update by completing a case report form. At least 1 of these case report forms was completed for 56 subjects.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=415 data updates
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Number of Data Updates Received by the uCor Subject Management System
3 data updates per subject
Interval 1.0 to 10.0

PRIMARY outcome

Timeframe: 90 days

Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. Sites reported whether they spent less than 5, 5 to 10, or greater than 10 minutes reviewing each report. At least 1 of these case report forms was completed for 214 subjects.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=2107 Number of data reports
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Approximate Time Spent Reviewing Data Reports Assessment Across Sites (PO 2: Part 1/2)
0-5 minutes
1548 Number of data reports
Approximate Time Spent Reviewing Data Reports Assessment Across Sites (PO 2: Part 1/2)
5-10 minutes
427 Number of data reports
Approximate Time Spent Reviewing Data Reports Assessment Across Sites (PO 2: Part 1/2)
>10 minutes
132 Number of data reports

PRIMARY outcome

Timeframe: 90 days

Population: Most common amount of time spent reviewing by each site

Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. Sites reported whether they spent less than 5, 5 to 10, or greater than 10 minutes reviewing each report. At least 1 of these case report forms was completed for 214 subjects.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=44 number of sites
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Approximate Time Spent Reviewing Data Reports Assessment Within Sites (PO 2: Part 2/2)
0-5 minutes
34 number of sites
Approximate Time Spent Reviewing Data Reports Assessment Within Sites (PO 2: Part 2/2)
5-10 minutes
9 number of sites
Approximate Time Spent Reviewing Data Reports Assessment Within Sites (PO 2: Part 2/2)
>10 minutes
1 number of sites

PRIMARY outcome

Timeframe: 90 days

Population: Number of medication changes or lifestyle modifications per subject based on μCor data and symptoms

Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects

Outcome measures

Outcome measures
Measure
uCor Wearers
n=159 number of MC/LS changes
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 1/3)
Number of medication changes based on μCor data and symptoms
114 number of MC/LS changes
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 1/3)
Number of lifestyle modifications based on μCor data and symptoms
45 number of MC/LS changes

PRIMARY outcome

Timeframe: 90 days

Population: Number of subjects with medication changes based on μCor data and symptoms

Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=68 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 2/3)
Number of subjects with 1 medication change(s) based on μCor data and symptoms
38 Participants
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 2/3)
Number of subjects with 2 medication change(s) based on μCor data and symptoms
19 Participants
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 2/3)
Number of subjects with 3+ medication change(s) based on μCor data and symptoms
11 Participants

PRIMARY outcome

Timeframe: 90 days

Population: Number of subjects with lifestyle modifications based on μCor data and symptoms

Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects

Outcome measures

Outcome measures
Measure
uCor Wearers
n=17 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 3/3)
Number of subjects with 1 lifestyle modification(s) based on μCor data and symptoms
8 Participants
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 3/3)
Number of subjects with 2 lifestyle modification(s) based on μCor data and symptoms
2 Participants
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 3/3)
Number of subjects with 3 lifestyle modification(s) based on μCor data and symptoms
3 Participants
The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 3/3)
Number of subjects with 4+ lifestyle modification(s) based on μCor data and symptoms
4 Participants

PRIMARY outcome

Timeframe: 90 days

Population: Subjects with Medication Changes (MC) based on incidental findings

During weekly planned phone calls, planned office visits, and unplanned office visits, sites asked subjects whether they underwent any changes to their heart failure and/or cardiac medications since the last phone call and reported the result in a case report form. At least 1 of these case report forms was completed for 241 subjects.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=139 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
The Number of Medication Changes Based on Subject Incidental Findings
Number of subjects with 2 medication change(s) based on incidental findings
35 Participants
The Number of Medication Changes Based on Subject Incidental Findings
Number of subjects with 3 medication change(s) based on incidental findings
20 Participants
The Number of Medication Changes Based on Subject Incidental Findings
Number of subjects with 1 medication change(s) based on incidental findings
58 Participants
The Number of Medication Changes Based on Subject Incidental Findings
Number of subjects with 4 medication change(s) based on incidental findings
10 Participants
The Number of Medication Changes Based on Subject Incidental Findings
Number of subjects with 5 medication change(s) based on incidental findings
8 Participants
The Number of Medication Changes Based on Subject Incidental Findings
Number of subjects with 6+ medication change(s) based on incidental findings
8 Participants

PRIMARY outcome

Timeframe: 90 days

Population: MC/LS events preceded by a high uCor measurement within -13 to 0 days

482 medication changes or lifestyle (MC/LS) modifications occurred within the first 90 days of the study. To include only medication changes preceded and followed by sufficient µCor data to determine a threshold crossing, medication changes within the first 2 weeks of the study or the final 3 weeks of device wear were discarded. This resulted in in 262 analyzable changes. Changes occurring within 1 week of another change were grouped together. This resulted in 192 change events. Time windows were defined as 0-13 days before the first change in a change event vs. 8-21 days after the last change in a change event. A high μCor measurement was defined as the receipt of a data update by the site. A low μCor measurement was defined as the absence of a data update received by the site.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=40 MC/LS change events
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Number of Times High μCor Measurements Were Reduced Below Threshold Levels After Medication Was Titrated or Lifestyle Modifications Were Recommended
MC/LS preceded by a high μCor meas. w/i -13 to 0 days,followed by a high uCor meas. w/i +8 to+21days
19 MC/LS change events
Number of Times High μCor Measurements Were Reduced Below Threshold Levels After Medication Was Titrated or Lifestyle Modifications Were Recommended
MC/LS preceded by a high μCor meas. w/i -13 to 0 days,followed by a low uCor meas. w/i +8 to+21 days
21 MC/LS change events

SECONDARY outcome

Timeframe: 90 days

Population: The median was calculated for the 7 days prior to the 1st heart failure (HF) event; the median was calculated for the final 7 days of device wear. ROC analysis was performed. Data are presented assuming that the device reading in subjects without events is less than that of subjects with events. Unit of measure: probability that a randomly chosen subject with severe symptoms has a greater device value than a randomly chosen subject with mild symptoms.

Definitions: Daytime: 7:00 AM - 12:00 AM Nighttime: 12:00 AM - 7:00 AM For each day on which the subject wore the device, the following values were calculated: Daytime activity: The proportion of minutes while wearing the device that the subject spent active (unitless). Nighttime heart rate: The median heart rate while wearing the device during the night (beats/min) Thoracic fluid index: The median proportion of ratio of radiofrequency-measured lung fluid readings compared to the subject's baseline (unitless). Nighttime posture: The median pitch angle while wearing the device during the night (degrees, where 0 is the horizontal). Nighttime respiration: The median respiration rate while wearing the device during the night (breaths/min) HF event: a hospitalization, emergency room visit, observation unit visit, unplanned clinic visit, or death primarily due to heart failure.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=249 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Strength of Association Between μCor Measurements and Clinically Related Heart Failure Events.
Daytime Activity
0.45 probability
Interval 0.34 to 0.57
Strength of Association Between μCor Measurements and Clinically Related Heart Failure Events.
Nighttime Heart Rate
0.57 probability
Interval 0.45 to 0.68
Strength of Association Between μCor Measurements and Clinically Related Heart Failure Events.
Nighttime Respiration Rate
0.52 probability
Interval 0.39 to 0.66
Strength of Association Between μCor Measurements and Clinically Related Heart Failure Events.
Nighttime Posture
0.57 probability
Interval 0.46 to 0.68
Strength of Association Between μCor Measurements and Clinically Related Heart Failure Events.
Thoracic Fluid Index
0.61 probability
Interval 0.51 to 0.71

SECONDARY outcome

Timeframe: 90 days

Population: The median of the daily medians for each device measure was calculated for the 7 days preceding each office visit. To assess whether reports of severe \[frequent or continuous\] symptoms were associated with greater device measures than reports of mild symptoms \[none or seldom\], ROC analysis was performed. Unit of measure: probability that a randomly chosen subject with severe symptoms has a greater device value than a randomly chosen subject with mild symptoms.

During office visits at months 1, 2, and 3, subjects reported their degrees of dyspnea, orthopnea, and fatigue on the following scale: \[none, seldom, frequent, continuous\]. Each day that the subject wore the device, a daily median was calculated for the following measures: \[thoracic fluid index, nighttime heart rate, nighttime respiration rate\]. Nighttime was defined as 12:00 AM - 7:00 AM.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=249 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Dyspnea and Thoracic Fluid Index (TFI)
0.54 probability
Interval 0.47 to 0.61
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Dyspnea and Nighttime Heart Rate
0.49 probability
Interval 0.42 to 0.56
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Dyspnea and Nighttime Respiration Rate
0.52 probability
Interval 0.45 to 0.59
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Orthopnea and Thoracic Fluid Index (TFI)
0.52 probability
Interval 0.44 to 0.61
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Orthopnea and Nighttime Heart Rate
0.53 probability
Interval 0.44 to 0.62
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Orthopnea and Nighttime Respiration Rate
0.60 probability
Interval 0.52 to 0.69
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Fatigue and Thoracic Fluid Index (TFI)
0.57 probability
Interval 0.5 to 0.63
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Fatigue and Nighttime Heart Rate
0.51 probability
Interval 0.45 to 0.58
Strength of Association Between μCor Measurements and Subject Reported Symptoms
Fatigue and Nighttime Respiration Rate
0.54 probability
Interval 0.48 to 0.61

SECONDARY outcome

Timeframe: 90 days

Population: Each of the 249 participants in the study could contribute data to either Arm/Group depending on the severity of their symptoms across the 3-month study duration.

During office visits at months 1, 2, and 3, subjects reported their degrees of dyspnea, orthopnea, and fatigue on the following scale: \[none, seldom, frequent, continuous\].

Outcome measures

Outcome measures
Measure
uCor Wearers
n=249 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
n=249 Participants
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Dyspnea - Thoracic Fluid Index (TFI)
255 Symptom reports
100 Symptom reports
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Orthopnea - Thoracic Fluid Index (TFI)
299 Symptom reports
56 Symptom reports
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Dyspnea - Nighttime Heart Rate (NHR)
253 Symptom reports
99 Symptom reports
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Dyspnea - Nighttime Respiration Rate (NRR)
254 Symptom reports
99 Symptom reports
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Orthopnea - Nighttime Heart Rate (NHR)
294 Symptom reports
57 Symptom reports
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Orthopnea - Nighttime Respiration Rate (NRR)
296 Symptom reports
56 Symptom reports
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Fatigue - Thoracic Fluid Index (TFI)
232 Symptom reports
123 Symptom reports
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Fatigue - Nighttime Heart Rate (NHR)
227 Symptom reports
124 Symptom reports
Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms
Fatigue - Nighttime Respiration Rate (NRR)
230 Symptom reports
122 Symptom reports

SECONDARY outcome

Timeframe: 90 days

Population: Subjects who had hospital readmission, physician visit, and/or outpatient clinic visit during the study period

For each weekly phone call and monthly office visit, each subject reported whether they experienced a hospitalization or emergency room visit since their last call/visit. An adjudication committee of physicians determined whether each event was due to HF or not.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=39 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Hospital Readmission Rate, Physician Visit Rate, and Outpatient Clinic Visit Rate During the Study Period
Subjects with Hospital Readmission for Heart Failure between enrollment and Day 90
32 Participants
Hospital Readmission Rate, Physician Visit Rate, and Outpatient Clinic Visit Rate During the Study Period
Subjects with an ER visit for Heart Failure between enrollment and Day 90
7 Participants

SECONDARY outcome

Timeframe: 6 months and 1 year

Population: Descriptive statistics around mortality rate, cause of death, quality of life (QoL), and health care utilization among patients six months and one year after enrollment into the study.

On each subject's final date of study participation, their survival status was recorded.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=249 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
n=249 Participants
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Mortality Data
Number of Subjects reported as deceased
20 Participants
37 Participants
Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Mortality Data
Number of Subjects not reported as deceased
229 Participants
212 Participants

SECONDARY outcome

Timeframe: 6 months and 1 year

Population: Descriptive statistics around mortality rate, cause of death, quality of life (QoL), and health care utilization among patients six months and one year after enrollment into the study.

On each subject's final date of study participation, in the case of death, the cause of death was recorded.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=37 Deaths
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Mortality Rate, Cause of Death, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Cause of Death
Cardiac-Sudden Cardiac Arrest
2 Deaths
Mortality Rate, Cause of Death, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Cause of Death
Cardiac-Heart Failure
10 Deaths
Mortality Rate, Cause of Death, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Cause of Death
Cardiac-Hypotension
1 Deaths
Mortality Rate, Cause of Death, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Cause of Death
Cardiac-Heart Disease
1 Deaths
Mortality Rate, Cause of Death, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Cause of Death
Non-cardiac
12 Deaths
Mortality Rate, Cause of Death, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Cause of Death
Unknown
11 Deaths

SECONDARY outcome

Timeframe: 6 months and 1 year

Population: Descriptive statistics around mortality rate, cause of death, quality of life (QoL), and health care utilization among patients six months and one year after enrollment into the study.

At 0 months, 6 months, and 1 year after enrollment, subjects completed a Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Quality of life is calculated as: KCCQ12-QL = 100\*\[(average of Questions 6 and 7) - 1\]/4 Score is scaled 0-100, where 0 denotes the lowest reportable health status and 100 the highest.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=249 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
n=96 Participants
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
n=90 Participants
Subjects still active in the study at 1 year post-enrollment.
Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Quality of Life Data
32 score on a scale
Standard Deviation 27.1
54.8 score on a scale
Standard Deviation 28.3
58.2 score on a scale
Standard Deviation 24.9

SECONDARY outcome

Timeframe: 6 months and 1 year

Population: All subjects in the study from the timepoint of enrollment until end of study participation.

For each weekly phone call, monthly office visit, 6-month phone call, and 1-year phone call, each subject reported whether they experienced a hospitalization, emergency room visit, or unplanned doctor's office visit since their last call/visit.

Outcome measures

Outcome measures
Measure
uCor Wearers
n=249 Participants
Subjects wearing the uCor device
uCor Wearers Reporting Severe Symptoms
n=249 Participants
Subjects wearing the uCor device that reported severe symptoms that were preceded by a valid device measure.
uCor Wearers - 1 Year Data
Subjects still active in the study at 1 year post-enrollment.
Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Healthcare Utilization Data
Subjects with hospitalization for any reason
120 participants
134 participants
Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Healthcare Utilization Data
Subjects with ER visit for any reason
101 participants
119 participants
Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Healthcare Utilization Data
Subjects with unplanned doctor's office visit for any reason
55 participants
62 participants

Adverse Events

Single-Arm, Eligible Subjects

Serious events: 0 serious events
Other events: 106 other events
Deaths: 37 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Single-Arm, Eligible Subjects
n=265 participants at risk
Subjects hospitalized for acute decompensated heart failure and enrolled in the study within 10 days post-hospital discharge. All subjects require an additional heart failure event within the previous 180 days.
Skin and subcutaneous tissue disorders
Skin Irritation
40.0%
106/265 • Number of events 143 • 1 year + 30 days, per subject
All device related adverse effects will be recorded during the study. All adverse device effects (ADEs) will be classified by the investigator as anticipated or unanticipated. Adverse events will also include any adverse events related to medication changes and medical procedures initiated by μCor data.

Additional Information

Director of Scientific Affairs

ZOLL Medical

Phone: 4129683333

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place